Could a lower dose of radiation plus a targeted pill treat this lymphoma just as well?
NCT ID NCT07705308
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study is for people with a slow-growing type of lymphoma called MALT lymphoma that has not spread. It compares a very low dose of radiation (4 Gy) combined with the targeted drug orelabrutinib against the standard higher dose of radiation (24 Gy). The goal is to see if the gentler combination can shrink tumors just as effectively while causing fewer side effects. About 140 adults with confirmed MALT lymphoma will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of low-dose radiotherapy (4 Gy) and a targeted drug called orelabrutinib
- What this could lead to
- If successful, this approach could offer a gentler, effective treatment option for localized MALT lymphoma, potentially reducing long-term side effects from standard radiation.
- What could go wrong
- This is a Phase 2 trial, so results are preliminary. The combination may not improve outcomes over standard therapy, and there could be unexpected side effects from the drug or radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Affiliated Minhang Hospital
Shanghai, Shanghai Municipality, China
-
Huadong Hospital
Shanghai, Shanghai Municipality, China
-
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.